Advancements in AML Treatment in the Past 10 Years

The field of acute myeloid leukemia (AML) treatment has undergone significant advancements in the past decade, leading to improved outcomes for many patients.

For patients with FLT3 mutations, targeted inhibitors have become a standard of care, improving response rates and survival. Drugs targeting IDH1 and IDH2 mutations have shown promising results, particularly in older patients. Additionally, venetoclax (Venclexta) a BCL-2 inhibitor, has revolutionized treatment for older patients, offering a less toxic alternative to intensive chemotherapy.

Overall, the past decade has seen a remarkable transformation in the treatment landscape for AML. These advancements have led to improved outcomes for many patients, particularly those with previously limited treatment options. Continued research and development are expected to further enhance the effectiveness of AML therapies in the future.

Here, Sangeetha Venugopal, MD, MS, physician in the Department of Medicine, Division of Hematology, at the Sylvester Comprehensive Cancer Center at the University of Miami, discusses the evolving field of acute myeloid leukemia treatment.

Transcription:

0:05 | I started my fellowship in 2017, so 2017 was the first year that saw the approval of midostaurin [Rydapt], which targets against FLT3 mutation. So since then, we have had a number of drugs approved for special molecular subsets, and that has changed the treatment landscape of AML immeasurably, and especially FLT3, we have now three drugs that targets the mutation because it's one of the [most common] molecular subgroups. So that's midostaurin, which, which is which targets FLT3 ITD and TKD, and gilteritinib [Xospata] again, which targets both FLT3 ITD and TKD, and quizartinib [Vanflyta] which targets FLT3 ITD.

0:51 | And we have a couple of others, which is IDH1, and we have 2 medications to that target, the IDH1 mutation. One is ivosidenib [Tibsovo] and other one is olutasidenib [Rezlidhia], which was approved recently. And for IDH2, we have enasidenib [Idhifa] for molecularly targeted therapies. The other exciting aspect that I'm looking forward is we have a new kid in the block, which is a Menin inhibitor, and that targets against NPM1 mutation and MLL or KMT2A rearrangements. I'm so looking forward to how this is going to play out for Menin inhibitors. The study was recently published.

Transcription generated with AI and edited for clarity.